Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in an outbreak of SARS-CoV-2
<p>In COVID-19, hypertension, diabetes mellitus, coronary artery disease, and immunosuppression are comorbid conditions most often associated with poor prognosis. Angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers are widely used in the treatment of these diseases. T...
Guardado en:
Autor principal: | Didar Yanardag Acik (Autor) |
---|---|
Formato: | Libro |
Publicado: |
Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,
2020-07-02.
|
Materias: | |
Acceso en línea: | Connect to this object online. |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Myla E. Moretti, et al.
Publicado: (2012) -
Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
por: Letian Zhou, et al.
Publicado: (2014) -
Effects of Spironolactone in Combination with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Proteinuria
por: Ha Yeon Kim, et al.
Publicado: (2014) -
Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Hye-Ran Jun, et al.
Publicado: (2021) -
Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
por: Yudi Her Oktaviono, et al.
Publicado: (2020)